Back to Industry News
General
Novo-Backed MapLight Therapeutics Files for IPO Amidst Biotech Market Headwinds
Summary generated with AI, editor-reviewed
Heartspace News Desk
•Source: Bloomberg
Photo by Dario Morandotti on Unsplash
Stay updated on stories like this
Key takeaways
- Novo-backed MapLight Therapeutics Inc
- , a clinical-stage biopharmaceutical company, has filed for an initial public offering (IPO), according to Bloomberg
- This move is particularly noteworthy, as MapLight is one of the few biotechnology firms pursuing a public listing in what has been a challenging year for the sector
Novo-backed MapLight Therapeutics Inc., a clinical-stage biopharmaceutical company, has filed for an initial public offering (IPO), according to Bloomberg. This move is particularly noteworthy, as MapLight is one of the few biotechnology firms pursuing a public listing in what has been a challenging year for the sector.
Based in Redwood City, California, MapLight submitted its filing with the U.S. Securities and Exchange Commission on Friday. The filing indicates that the company's lead product candidate, a fixed-dose combination of two distinct drugs, is under development for the treatment of schizophrenia and Alzheimer's disease psychosis (ADP).
Related Topics
BiotechnologyIPONovoMapLight TherapeuticsSchizophreniaAlzheimer's Disease PsychosisClinical Stage
Never miss stories like this